Vadis trial: phase II trial of E75 peptide vaccine in women with dcis of the breast
Ended Awarded Last action
- Contract number
- HHSN26100009
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $501,636
Award facts
- Contract value 40% obligated
-
- $501,635.75 Current, with exercised options
- $1,253,018.75 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$20,792 | |
| Change Order | $0 | |
| Funding Only Action | $58,235 | |
| Supplemental Agreement for work within scope | $12,545 | |
| Original award | $451,648 |
About this award
This is a $1,253,018.75 delivery order awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for the VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST. The contract is part of the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery contract. The award supports an early phase clinical research study evaluating a cancer prevention vaccine. MD Anderson is a comprehensive cancer treatment and research center that regularly receives federal prime and subcontract awards to conduct cancer research, including clinical trials, for agencies like the NIH and Department of Defense. This contract does not have a set-aside designation.
Quick answers
Who was awarded contract HHSN26100009?
HHSN26100009 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 15, 2015.
How much is contract HHSN26100009 worth?
The government has obligated $501,636 on HHSN26100009. Its potential value, with all options, is $1,253,019.
Is contract HHSN26100009 an order under another contract?
Yes. HHSN26100009 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100009 competed?
The extent of competition for HHSN26100009 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award